A widely available and affordable blood-thinning drug, heparin, limits lung damage when inhaled by Covid-19 patients, and may also prevent infection from the SARS-CoV-2 virus, according to early results of a study. Researchers from the Australian National University (ANU) and colleagues are tracking hospital patients infected with SARS-CoV-2 in 13 countries who were given
A widely available and affordable drug, heparin, limits lung damage when inhaled by COVID-19 patients, according to world-first findings by researchers from The Australian National University (ANU).
Researchers from King s College London and the Australian National University found heparin - which costs around £33 per dose - improves oxygen levels by 70 per cent in virus patients.